BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 28699177)

  • 1. Association between age-related reductions in testosterone and risk of prostate cancer-An analysis of patients' data with prostatic diseases.
    Wang K; Chen X; Bird VY; Gerke TA; Manini TM; Prosperi M
    Int J Cancer; 2017 Nov; 141(9):1783-1793. PubMed ID: 28699177
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Higher sex hormone-binding globulin and lower bioavailable testosterone are related to prostate cancer detection on prostate biopsy.
    García-Cruz E; Carrión Puig A; García-Larrosa A; Sallent A; Castañeda-Argáiz R; Piqueras M; Ribal MJ; Leibar-Tamayo A; Romero-Otero J; Alcaraz A
    Scand J Urol; 2013 Aug; 47(4):282-9. PubMed ID: 23181478
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum testosterone and dihydrotestosterone and prostate cancer risk in the placebo arm of the Reduction by Dutasteride of Prostate Cancer Events trial.
    Muller RL; Gerber L; Moreira DM; Andriole G; Castro-Santamaria R; Freedland SJ
    Eur Urol; 2012 Nov; 62(5):757-64. PubMed ID: 22658758
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Low testosterone bioavailability is related to prostate cancer diagnose in patients submitted to prostate biopsy.
    García-Cruz E; Huguet J; Piqueras M; Márquez MP; Peri L; Izquierdo L; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    World J Urol; 2012 Jun; 30(3):361-5. PubMed ID: 21833558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low testosterone levels are related to poor prognosis factors in men with prostate cancer prior to treatment.
    García-Cruz E; Piqueras M; Huguet J; Peri L; Izquierdo L; Musquera M; Franco A; Alvarez-Vijande R; Ribal MJ; Alcaraz A
    BJU Int; 2012 Dec; 110(11 Pt B):E541-6. PubMed ID: 22584031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Additional value of the ratio of serum total testosterone to total prostate-specific antigen in the diagnosis of prostate cancer in a Chinese population.
    Xu L; Hu X; Zhu Y; Lu J; Xu Y; Wang G; Guo J
    Andrologia; 2018 Mar; 50(2):. PubMed ID: 28752596
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Greater percent-free testosterone is associated with high-grade prostate cancer in men undergoing prostate biopsy.
    Albisinni S; De Nunzio C; Tubaro A; Barry WT; Banez LL; Freedland SJ
    Urology; 2012 Jul; 80(1):162-7. PubMed ID: 22608797
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic Properties of Total and Free Prostate-Specific Antigen to Predict Overall and Clinically Significant Prostate Cancer Among Men With Low Testosterone and Prior Negative Biopsy.
    Schwarzman LS; Pagani RL; Ohlander SJ; Mima M; Abern MR; Andriole GL; Freedland SJ; Moreira DM
    Urology; 2020 Mar; 137():97-101. PubMed ID: 31733275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Differentiation of prostate cancer from benign prostatic disease by total prostate specific antigen dynamic profiles after transrectal prostate biopsy].
    Shao Q; Song J; Zhou ZJ; Du LD
    Zhonghua Nan Ke Xue; 2008 Jul; 14(7):597-601. PubMed ID: 18686378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low pretreatment serum total testosterone is associated with a high incidence of Gleason score 8-10 disease in prostatectomy specimens: data from ethnic Chinese patients with localized prostate cancer.
    Dai B; Qu Y; Kong Y; Ye D; Yao X; Zhang S; Wang C; Zhang H; Yang W
    BJU Int; 2012 Dec; 110(11 Pt B):E667-72. PubMed ID: 22974446
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Polymorphism in ARE-I region of prostate-specific antigen gene associated with low serum testosterone level and high-grade prostate cancer.
    Schatzl G; Marberger M; Remzi M; Grösser P; Unterlechner J; Haidinger G; Zidek T; Preyer M; Micksche M; Gsur A
    Urology; 2005 Jun; 65(6):1141-5. PubMed ID: 15893813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer.
    Friedersdorff F; Manus P; Miller K; Lein M; Jung K; Stephan C
    Clin Biochem; 2014 Jul; 47(10-11):916-20. PubMed ID: 24530341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Aggressiveness of Localized Prostate Cancer: the Key Value of Testosterone Deficiency Evaluated by Both Total and Bioavailable Testosterone: AndroCan Study Results.
    Neuzillet Y; Raynaud JP; Dreyfus JF; Radulescu C; Rouanne M; Schneider M; Krish S; Rouprêt M; Drouin SJ; Comperat E; Galiano M; Cathelineau X; Validire P; Molinié V; Fiet J; Giton F; Lebret T; Botto H
    Horm Cancer; 2019 Feb; 10(1):36-44. PubMed ID: 30293206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two years of testosterone therapy associated with decline in prostate-specific antigen in a man with untreated prostate cancer.
    Morgentaler A
    J Sex Med; 2009 Feb; 6(2):574-7. PubMed ID: 19215619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hormonal predictors of prostate cancer.
    Sofikerim M; Eskicorapci S; Oruç O; Ozen H
    Urol Int; 2007; 79(1):13-8. PubMed ID: 17627161
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Low testosterone level predicts prostate cancer in re-biopsy in patients with high grade prostatic intraepithelial neoplasia.
    García-Cruz E; Piqueras M; Ribal MJ; Huguet J; Serapiao R; Peri L; Izquierdo L; Alcaraz A
    BJU Int; 2012 Sep; 110(6 Pt B):E199-202. PubMed ID: 22257176
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prostate Volume Index Is Able to Differentiate between Prostatic Chronic Inflammation and Prostate Cancer in Patients with Normal Digital Rectal Examination and Prostate-Specific Antigen Values <10 ng/mL: Results of 564 Biopsy Naïve Cases.
    Porcaro AB; Tafuri A; Sebben M; Novella G; Processali T; Pirozzi M; Amigoni N; Rizzetto R; Shakir A; Panunzio A; De Michele M; Brunelli M; Cerruto MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2019; 103(4):415-422. PubMed ID: 31466070
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Serum testosterone as a biomarker for second prostatic biopsy in men with negative first biopsy for prostatic cancer and PSA>4ng/mL, or with PIN biopsy result.
    Fiamegos A; Varkarakis J; Kontraros M; Karagiannis A; Chrisofos M; Barbalias D; Deliveliotis C
    Int Braz J Urol; 2016; 42(5):925-931. PubMed ID: 27532110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
    Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
    Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low free testosterone levels predict disease reclassification in men with prostate cancer undergoing active surveillance.
    San Francisco IF; Rojas PA; DeWolf WC; Morgentaler A
    BJU Int; 2014 Aug; 114(2):229-35. PubMed ID: 24898919
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.